Shares of PROCEPT BioRobotics Corp. (PRCT) are gaining over 13% on Wednesday morning after the surgical robotics company FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System.
PRCPT is currently trading at $73.50, up $8.50 or 13.03%, on the Nasdaq. The stock opened its trading at $70.10 after closing Tuesday at $65.00. The stock has traded between $24.83 and $77.00 in the past 52-week period.
HYDROS features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes.
"We are pleased to bring the HYDROS Robotic System to the U.S. market," said Reza Zadno, CEO of PROCEPT BioRobotics. "This milestone marks a pivotal moment for PROCEPT as Aquablation therapy continues its rapid adoption, with over 400 robotic systems now installed across the United States. After years of research and development, HYDROS introduces significant technological advancements designed for mass-market adoption, and we believe will power the next phase of our growth."
"As a urologist, my goal is to treat my patients' symptoms while preserving their quality of life. Aquablation therapy has been instrumental in helping me achieve this for patients struggling with BPH," said Dr. Steven Kaplan, Icahn School of Medicine at Mount Sinai. "The HYDROS Robotic System advances this further by utilizing the power of AI to better read and interpret ultrasound for optimal surgical planning."
For comments and feedback: editorial@rttnews.com